IL242493B - Pharmaceutical formulations relieve radioactivity - Google Patents
Pharmaceutical formulations relieve radioactivityInfo
- Publication number
- IL242493B IL242493B IL242493A IL24249315A IL242493B IL 242493 B IL242493 B IL 242493B IL 242493 A IL242493 A IL 242493A IL 24249315 A IL24249315 A IL 24249315A IL 242493 B IL242493 B IL 242493B
- Authority
- IL
- Israel
- Prior art keywords
- radiomitigating
- phamaceutical
- formulations
- phamaceutical formulations
- radiomitigating phamaceutical
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361820447P | 2013-05-07 | 2013-05-07 | |
| PCT/US2014/037110 WO2014182789A2 (en) | 2013-05-07 | 2014-05-07 | Radiomitigating pharmaceutical formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL242493A0 IL242493A0 (en) | 2016-02-01 |
| IL242493B true IL242493B (en) | 2020-08-31 |
Family
ID=51867859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL242493A IL242493B (en) | 2013-05-07 | 2015-11-08 | Pharmaceutical formulations relieve radioactivity |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9783515B2 (enExample) |
| EP (1) | EP2994457B1 (enExample) |
| JP (1) | JP2016523830A (enExample) |
| KR (1) | KR20160005356A (enExample) |
| CN (1) | CN105579439B (enExample) |
| AU (1) | AU2014262764B2 (enExample) |
| CA (1) | CA2911902A1 (enExample) |
| ES (1) | ES2860949T3 (enExample) |
| IL (1) | IL242493B (enExample) |
| SG (1) | SG11201509194SA (enExample) |
| WO (1) | WO2014182789A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130203722A1 (en) | 2006-09-26 | 2013-08-08 | Rhonda R. Voskuhl | Estriol therapy for autoimmune and neurodegenerative disease and disorders |
| KR20160005356A (ko) * | 2013-05-07 | 2016-01-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 방사선완화 약제학적 제형 |
| WO2017156222A1 (en) * | 2016-03-09 | 2017-09-14 | The Regents Of The University Of California | Radiomitigating compounds, compositions and methods related thereto |
| AU2017342551B2 (en) * | 2016-10-16 | 2022-10-20 | BCN Biosciences L.L.C. | Methods of treatment and pharmaceutical compositions using BCN057 or BCN512 |
| AU2018316185A1 (en) * | 2017-08-08 | 2020-03-26 | BCN Biosciences L.L.C. | Methods of treating radiation induced gastrointestinal syndrome (RIGS) and related disease states using compound 512 |
| WO2023122723A1 (en) | 2021-12-23 | 2023-06-29 | The Broad Institute, Inc. | Panels and methods for diagnosing and treating lung cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4159331A (en) * | 1978-05-05 | 1979-06-26 | The Upjohn Company | Antihypertensive 4-aminoquinolines |
| SI20324A (sl) | 1997-10-27 | 2001-02-28 | Agouron Pharmaceuticals, Inc. | Substituirane 4-amino-tiazol-2-il spojine kot cdk inhibitorji |
| US6407120B1 (en) * | 1999-02-18 | 2002-06-18 | Pfizer Inc. | Neuropeptide Y antagonists |
| IT1313594B1 (it) * | 1999-08-03 | 2002-09-09 | Novuspharma Spa | Bisplatino complessi attivi per via orale. |
| JP4365102B2 (ja) * | 2001-04-26 | 2009-11-18 | コーロン ライフ サイエンス インク | 新規なスルホンアミド誘導体、その中間体化合物、及びその製造方法、並びにスルホンアミド誘導体を含む薬剤学的組成物 |
| HUE032523T2 (en) * | 2003-11-14 | 2017-09-28 | Temple Univ - Of The Commonwealth System Of Higher Education | Alpha, beta-unsaturated sulfoxides for the treatment of proliferative disorders |
| JP2005232101A (ja) * | 2004-02-20 | 2005-09-02 | Rikogaku Shinkokai | セレコキシブアミノアルキル誘導体 |
| US7345043B2 (en) | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
| MY140912A (en) | 2004-07-26 | 2010-01-29 | Du Pont | Mixtures of anthranilamide invertebrate pest control agents |
| US7615570B2 (en) * | 2004-12-13 | 2009-11-10 | Abbott Laboratories | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| WO2007029078A2 (en) * | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Succinimide and glutarimide derivatives as adrenergic receptor antagonists |
| WO2007143745A2 (en) | 2006-06-09 | 2007-12-13 | Icos Corporation | Substituted phenyl acetic acids as dp-2 antagonists |
| EA200900496A1 (ru) | 2006-09-28 | 2009-08-28 | Эрет Терэпьютикс, Инк. | Сульфонамидные соединения (варианты), содержащая их фармацевтическая композиция, способ ингибирования растворимой эпоксидгидролазы и способ лечения заболеваний, опосредованных растворимой эпоксидгидролазой |
| JP2011526925A (ja) | 2008-07-01 | 2011-10-20 | ザカロン ファーマシューティカルズ，インク． | ヘパラン硫酸阻害剤 |
| GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| WO2010111713A2 (en) * | 2009-03-27 | 2010-09-30 | Zacharon Pharmaceuticals, Inc. | N-linked glycan biosynthesis modulators |
| WO2012087889A2 (en) * | 2010-12-20 | 2012-06-28 | The Ohio State University Research Foundation | Dna methylation inhibitors |
| US9217000B2 (en) * | 2011-02-18 | 2015-12-22 | Univerisyt of Pittsburgh—of the Commonwealth System of Higher Education | Targeted nitroxide agents |
| KR20160005356A (ko) * | 2013-05-07 | 2016-01-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 방사선완화 약제학적 제형 |
-
2014
- 2014-05-07 KR KR1020157034769A patent/KR20160005356A/ko not_active Ceased
- 2014-05-07 WO PCT/US2014/037110 patent/WO2014182789A2/en not_active Ceased
- 2014-05-07 JP JP2016513039A patent/JP2016523830A/ja active Pending
- 2014-05-07 EP EP14794084.5A patent/EP2994457B1/en active Active
- 2014-05-07 AU AU2014262764A patent/AU2014262764B2/en active Active
- 2014-05-07 ES ES14794084T patent/ES2860949T3/es active Active
- 2014-05-07 SG SG11201509194SA patent/SG11201509194SA/en unknown
- 2014-05-07 US US14/889,719 patent/US9783515B2/en active Active
- 2014-05-07 CA CA2911902A patent/CA2911902A1/en not_active Abandoned
- 2014-05-07 CN CN201480038705.0A patent/CN105579439B/zh active Active
-
2015
- 2015-11-08 IL IL242493A patent/IL242493B/en active IP Right Grant
-
2016
- 2016-04-08 US US15/094,192 patent/US9840483B2/en active Active
-
2017
- 2017-11-14 US US15/812,321 patent/US20180162827A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160221976A1 (en) | 2016-08-04 |
| CN105579439B (zh) | 2018-10-19 |
| US9840483B2 (en) | 2017-12-12 |
| ES2860949T3 (es) | 2021-10-05 |
| KR20160005356A (ko) | 2016-01-14 |
| EP2994457B1 (en) | 2021-01-06 |
| US20160090369A1 (en) | 2016-03-31 |
| IL242493A0 (en) | 2016-02-01 |
| AU2014262764A1 (en) | 2015-12-17 |
| US9783515B2 (en) | 2017-10-10 |
| WO2014182789A2 (en) | 2014-11-13 |
| CN105579439A (zh) | 2016-05-11 |
| AU2014262764B2 (en) | 2018-11-15 |
| US20180162827A1 (en) | 2018-06-14 |
| JP2016523830A (ja) | 2016-08-12 |
| WO2014182789A3 (en) | 2014-12-11 |
| CA2911902A1 (en) | 2014-11-13 |
| EP2994457A2 (en) | 2016-03-16 |
| SG11201509194SA (en) | 2015-12-30 |
| EP2994457A4 (en) | 2016-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3088517T5 (en) | Humant anti-il-33-neutraliserende monoklonalt antistof | |
| GB201319791D0 (en) | Formulations | |
| GB201319792D0 (en) | Formulations | |
| IL245420A0 (en) | New formulations | |
| SG11201506882YA (en) | Ophthalmic formulations | |
| IL242493A0 (en) | Pharmaceutical formulations relieve radioactivity | |
| AU353643S (en) | Stamphousing | |
| GB201322948D0 (en) | Improved formulation | |
| GB2510633B (en) | Temporary pathway | |
| GB201301329D0 (en) | Fluidfoil | |
| GB2517232B (en) | Formulation | |
| GB201413253D0 (en) | Solid dosage form | |
| GB201306901D0 (en) | Combination | |
| AU4977P (en) | Harrosy Gaura lindheimeri | |
| GB201319352D0 (en) | Formulation | |
| GB201320647D0 (en) | Immunoconjugates | |
| GB201318043D0 (en) | Immunoconjugates | |
| GB201312347D0 (en) | Formulation | |
| GB201318451D0 (en) | W/C Sani-vent | |
| GB201307599D0 (en) | Immunoconjugates | |
| GB201316662D0 (en) | Pharmaceutical Combination | |
| GB201307081D0 (en) | Combines | |
| GB201318303D0 (en) | Bedpan | |
| GB201302952D0 (en) | Easily fitted longerie | |
| GB201317353D0 (en) | Ed |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |